Evidence map›Paper›PMID 23525419›Full record

Trial reportJournal of the American Heart Association2013

Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study.

Mary Clare Luca, Andrew Liuni, Kelsey McLaughlin, Tommaso Gori, John D Parker

2 registry-linked trialsOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02506062 nacompletednot on this mapstarted 2015, after this paper: background citation

A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2015 to 2018Enrolled21ConditionsRaynaud Disease, Raynaud's PhenomenonArmsManual blood pressure cuff inflation over brachial artery
NCT03236350 naunknown statusnot on this mapstarted 2017, after this paper: background citation

The Effect of Remote Ischaemic Conditioning on Blood Pressure Control in Patients With Chronic Kidney Disease - the ERIC-BP-CKD Trial

TypeinterventionalSponsorSingapore General HospitalRan2017 to 2020Enrolled85ConditionsChronic Kidney Diseases, Hypertension, Cardiovascular DiseasesArmsActive autoRIC® (CRIC Treatment), Sham Control autoRIC® (Sham Control)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. From ischemic conditioning to 'hyperconditioning': clinical phenomenon and basic science opportunity.Dose-response : a publication of International Hormesis Society · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Mary Clare LucaDivision of Cardiology, Mount Sinai and University Health Network Hospitals, Toronto, Canada.
Andrew Liuni
Kelsey McLaughlin
Tommaso Gori
John D Parker
University Health Network · CAJohannes Gutenberg University Mainz · DEMount Sinai Hospital · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is well established that acute ischemic preconditioning (IPC) protects against ischemia-reperfusion (IR) injury; however, the effectiveness of repeated IPC exposure has not been extensively investigated. We aimed to determine whether daily IPC episodes provide continued protection from IR injury in a human forearm model, and the role of cyclooxygenase-2 in these responses. METHODS AND

resultsThirty healthy volunteers were randomized to participate in 2 of 3 protocols (IR alone, 1-day IPC, 7-day IPC) in an operator-blinded, crossover design. Subjects in the IR alone protocol underwent flow-mediated dilation (FMD) measurements pre- and post-IR (15' upper-arm ischemia and 15' reperfusion). The 1-day IPC protocol involved FMD measurements before and after 1 episode of IPC (3 cycles of 5' upper-arm ischemia and 5' reperfusion) and IR. Day 7 of the 7-day IPC protocol was identical to the 1-day IPC protocol but was preceded by single daily episodes of IPC for 6 days prior. During each protocol, subjects received a 7-day treatment of either the cyclooxygenase-2 inhibitor celecoxib or placebo. Pre-IR FMD was similar between groups. IR alone reduced FMD post-IR (placebo, ΔFMD: -4.4±0.7%; celecoxib, ΔFMD: -5.0±0.5%). One-day IPC completely prevented this effect (placebo, ΔFMD: -1.1±0.6%; celecoxib, ΔFMD: 0.0±0.7%; P<0.0001). Similarly, 7-day IPC demonstrated persistent endothelial protection post-IR (placebo, ΔFMD: -0.9±0.9%; celecoxib, ΔFMD: 0.0±0.8%; P<0.0001, P<0.0001 for ANOVA effect of IPC protocol). Celecoxib did not alter responses to IR in any protocol.

conclusionsDaily episodes of IPC provide sustained protection from IR-induced endothelial dysfunction in humans through a mechanism that appears cyclooxygenase-2-independent.

Indexed as

VasodilationAdultAnalysis of VarianceCelecoxibCross-Over StudiesCyclooxygenase 2Cyclooxygenase 2 InhibitorsEndothelium, VascularForearmHumansHyperemiaIschemic PreconditioningMaleOntarioPyrazolesReperfusion InjuryCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsPTGS2 protein, humanPyrazolesSulfonamides

Identifiers

PMID23525419
PMCPMC3603254
OpenAlexW1969029060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.